INmune Bio Inc. (INMB)
NASDAQ: INMB
· Real-Time Price · USD
7.61
0.26 (3.54%)
At close: Jun 06, 2025, 3:59 PM
7.57
-0.53%
After-hours: Jun 06, 2025, 05:14 PM EDT
3.54% (1D)
| Bid | 7.4 |
| Market Cap | 176.63M |
| Revenue (ttm) | 50K |
| Net Income (ttm) | -40.8M |
| EPS (ttm) | -1.93 |
| PE Ratio (ttm) | -3.94 |
| Forward PE | -4.53 |
| Analyst | Buy |
| Ask | 7.76 |
| Volume | 399,542 |
| Avg. Volume (20D) | 281,050 |
| Open | 7.48 |
| Previous Close | 7.35 |
| Day's Range | 7.51 - 7.76 |
| 52-Week Range | 4.32 - 10.50 |
| Beta | 1.57 |
About INMB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INMB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INMB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+10.67%
Inmune Bio shares are trading higher after the com...
Unlock content with
Pro Subscription
7 months ago
+13.84%
INmune Bio shares are trading higher after the company announced it will host a webinar on cognitive testing using EMACC and CDR-SB on November 7 at 1 pm ET.
2 months ago · seekingalpha.com
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffe...
2 months ago · seekingalpha.com
INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's ResultsINmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billio...